Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 135, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2020.111169
Keywords
lncRNA; TTN-AS1; Biomarker; Diagnostic marker; Cancer; Progression
Funding
- National Science and Technology Major Project of China [2018ZX10302206, 2017ZX10202203]
- Zhejiang University Academic Award for Outstanding Doctoral Candidates [2020052]
Ask authors/readers for more resources
Long noncoding RNAs (lncRNAs) are a type of noncoding RNA over 200 nucleotides in length, involved in various biological processes in normal cells. Some lncRNAs may act as oncogenes or tumor suppressor genes in cancers. For example, TTN-AS1 has pro-oncogenic effects in multiple cancers, correlating with tumor malignancy and poor prognosis.
The long noncoding RNAs (lncRNAs) are non-coding RNAs that are more than 200 nucleotides in length, and one of several types of non-coding RNAs (ncRNAs). The lncRNAs function in diverse biological processes in normal cells, such as cellular differentiation and cell cycle regulation. There is also evidence that some aberrantly regulated lncRNAs function as oncogenes or tumor suppressor genes in various cancers. For example, TTN-AS1 is a lncRNA that binds to titin mRNA (TTN) and has pro-oncogenic effects in many cancers. Overexpression of TTNAS1 correlates with poor prognosis in breast cancer, lung cancer, digestive system neoplasms, reproductive system cancers, and other cancers. Furthermore, increased TTN-AS1 expression correlates with more advanced pathology and tumor malignancy. In this review, we comprehensively summarize recent studies on the molecular mechanisms of TTN-AS1 regulation and the role of TTN-AS1 in the carcinogenesis and progression of numerous tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available